Filana Therapeutics (FLNA)
Developing simufilam, an oral small molecule, for TSC-related epilepsy.
Something off on this page? Send us feedback.
Develops simufilam, its sole named drug candidate, for TSC-related epilepsy and other possible CNS indications involving filamin A. With no approved products or product-sales revenue, progress depends on addressing the FDA clinical hold for its proposed trial.
Develops simufilam, an oral small molecule being investigated for TSC-related epilepsy and other possible central-nervous-system indications involving filamin A. This Austin-based clinical-stage biotechnology business centers on a single named candidate and has no approved products or product-sales revenue. Its stated mission is to develop therapies for CNS disorders involving dysregulation or overexpression of filamin A.
Current development follows a pivot away from the discontinued Alzheimer's program. The proposed proof-of-concept TSC-related-epilepsy trial remains on full FDA clinical hold while Filana addresses additional preclinical-information and protocol-modification requests. Advancing the program depends on FDA review, clinical development, regulatory approval, manufacturing supply, and commercialization capabilities.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $82.7M · Total debt $0 · Total assets $103.9M · Shareholders' equity $63.6M
- Revenue
- $0
- Operating income
- −$9.4M
- Net income
- −$8.6M
No dividends on record.
No ownership filings on record for this listing.
- Jazz Pharmaceuticals
Epidiolex is an approved treatment for TSC-associated seizures
- Novartis (ADR)
Afinitor Disperz is approved adjunctive therapy for TSC seizures
- LivaNova
VNS Therapy offers neuromodulation for drug-resistant epilepsy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Filana Therapeutics | $1.05 | +41.31% | $35.7M | — | — | — | — |
| Jazz Pharmaceuticals | $241.30 | −0.07% | $15.17B | 16.5 | 9.6 | 3.3 | +15.6% |
| Novartis (ADR) | $141.62 | +0.45% | $267.96B | 21.3 | 15.1 | 4.8 | +0.9% |
| LivaNova | $78.60 | +0.56% | $4.29B | 23.1 | 17.8 | 2.9 | +10.8% |
| Median | 21.3 | 15.1 | 3.3 | +10.8% |